USTEKINUMAB CONCENTRATIONS INDUCTION IBD

This study looked at how the concentration of the drug ustekinumab (UST) during the first weeks of treatment affects gut healing in patients with Crohn’s disease and ulcerative colitis, two types of inflammatory bowel disease (IBD). The researchers followed 70 patients starting UST treatment and measured drug levels in the blood at week 8; then checked how well the treatment was working at week 24 based on clinical symptoms and findings in colonoscopy.Patients with higher UST levels at week 8 were more likely to have better healing of the bowel mucosa at week 24. In particular, patients with UST levels above 4.5 micrograms per milliliter had the best results. This level was a good predictor of who would achieve intestinal healing. However, a higher drug level did not mean that the treatment lasted longer overall.These results suggest that measuring UST levels at the start of treatment could help doctors predict how well a patient will respond to treatment and influence treatment decisions. Further research is needed to confirm that adjusting doses based on early drug levels can improve outcomes for patients with IBD.